Apogee Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Apogee Therapeutics's estimated annual revenue is currently $18.1M per year.
- Apogee Therapeutics's estimated revenue per employee is $85,141
Employee Data
- Apogee Therapeutics has 213 Employees.
- Apogee Therapeutics grew their employee count by 99% last year.
Apogee Therapeutics's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO at Apogee Therapeutics | Reveal Email/Phone |
2 | CEO | Reveal Email/Phone |
3 | Chief Commercial Officer | Reveal Email/Phone |
4 | Chief Financial Officer | Reveal Email/Phone |
5 | Chief Medical Officer | Reveal Email/Phone |
6 | Chief Medical Officer | Reveal Email/Phone |
7 | SVP Tax | Reveal Email/Phone |
8 | VP, Clinical Pharmacology | Reveal Email/Phone |
9 | SVP, Research & Translational Medicine | Reveal Email/Phone |
10 | SVP, Commercial Strategy & Operations | Reveal Email/Phone |
Apogee Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 5 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 4 | -50% | N/A | N/A |
#6 | $0.7M | 8 | 0% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 17 | 31% | N/A | N/A |
What Is Apogee Therapeutics?
Apogee Therapeutics, LLC is a biotechnology company advancing novel, potentially best-in-class therapies to address the needs of the millions of people living with immunological and inflammatory disorders.
keywords:N/AN/A
Total Funding
213
Number of Employees
$18.1M
Revenue (est)
99%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $34M | 213 | 52% | N/A |
#2 | $21M | 213 | 47% | $161M |
#3 | $24.2M | 213 | 35% | $115M |
#4 | $65.9M | 213 | 47% | $161M |
#5 | N/A | 214 | 5% | N/A |